Bavarian Nordic Secures $22.5M Mpox/Smallpox Vaccine Order from Canada
Event summary
- Bavarian Nordic received a $22.5M order from Canada for its MVA-BN® mpox/smallpox vaccine under an existing 10-year contract framework.
- The order will support 2026 manufacturing, with final drug product supply scheduled for later.
- This brings Bavarian Nordic's 2026 Public Preparedness business orders to ~DKK 1.4B, up DKK 100M from previous guidance.
- Full-year 2026 guidance for this segment remains DKK 1.8B-2.0B.
The big picture
This order reinforces Bavarian Nordic's role as a key supplier in global biodefense preparedness, particularly for non-replicating vaccines. The deal comes as governments increasingly prioritize pandemic readiness, with Bavarian Nordic positioning itself as a multi-government partner through frameworks like BARDA and HERA. The $22.5M contract represents a modest but strategic addition to its 2026 revenue outlook.
What we're watching
- Government Demand
- Whether Canada's order signals sustained public health investment in mpox/smallpox vaccines amid shifting global health priorities.
- Production Capacity
- The pace at which Bavarian Nordic can scale manufacturing to meet increased demand from multiple government partners.
- Competitive Positioning
- How Bavarian Nordic's non-replicating vaccine differentiates it in the smallpox/mpox vaccine market.